ERCC1 and clinical resistance to platinum-based therapy

被引:112
作者
Reed, E [1 ]
机构
[1] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA 30341 USA
关键词
D O I
10.1158/1078-0432.CCR-05-1083
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:6100 / 6102
页数:3
相关论文
共 27 条
[1]  
Altaha R, 2004, INT J MOL MED, V14, P959
[2]   Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines [J].
Bonovich, M ;
Olive, M ;
Reed, E ;
O'Connell, B ;
Vinson, C .
CANCER GENE THERAPY, 2002, 9 (01) :62-70
[3]   EXPRESSION OF EXCISION REPAIR GENES IN NONMALIGNANT BONE-MARROW FROM CANCER-PATIENTS [J].
DABHOLKAR, M ;
BOSTICKBRUTON, F ;
WEBER, C ;
EGWUAGU, C ;
BOHR, VA ;
REED, E .
MUTATION RESEARCH, 1993, 293 (02) :151-160
[4]   Increased mRNA levels of Xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum resistant human ovarian cancer tissues [J].
Dabholkar, M ;
Thornton, K ;
Vionnet, J ;
Bostick-Bruton, F ;
Yu, JJ ;
Reed, E .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (11) :1611-1619
[5]  
DABHOLKAR M, 1995, ONCOL REP, V2, P209
[6]   ERCC1 AND ERCC2 EXPRESSION IN MALIGNANT-TISSUES FROM OVARIAN-CANCER PATIENTS [J].
DABHOLKAR, M ;
BOSTICKBRUTON, F ;
WEBER, C ;
BOHR, VA ;
EGWUAGU, C ;
REED, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (19) :1512-1517
[7]   MESSENGER-RNA LEVELS OF XPAC AND ERCC1 IN OVARIAN-CANCER TISSUE CORRELATE WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY [J].
DABHOLKAR, M ;
VIONNET, J ;
BOSTICKBRUTON, F ;
YU, JJ ;
REED, E .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (02) :703-708
[8]  
Dabholkar MD, 1996, MOL CARCINOGEN, V17, P1, DOI 10.1002/(SICI)1098-2744(199609)17:1<1::AID-MC1>3.0.CO
[9]  
2-M
[10]  
DABHOLKAR MD, 1995, CANCER RES, V55, P1261